ProPhase Labs Exceeding Initial Goals as Covid-19 Lab Testing Business Ramps up - Seite 2
Mr. Karkus further explained: “At present, our margins appear to be generating significantly greater than $30 net profit per test. However, until we have more experience with reimbursement rates, it will be difficult to estimate how much higher the actual profit per test might be.”
The Company emphasized that the future testing revenues and margins discussed herein cannot be assured and are subject to numerous factors and risks outside of the Company’s control.
ProPhase will host a shareholder conference call on February 10, 2021 to review the performance of its laboratory processing business, short- and long-term prospects for future growth, and strategic direction.
ProPhase Labs Shareholder Conference Call
Date: | Wednesday, February 10, 2021 |
Time: | 11:00 a.m. Eastern time (8:00 a.m. Pacific time) |
Dial-in: | 1-877-407-0784 |
International Dial-in: | 1-201-689-8560 |
Passcode: | 13716077 |
Webcast: | http://public.viavid.com/index.php?id=143390 |
A telephone replay will be available approximately two hours after the call and will run through March 10, 2021 by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13716077.
The webcast will be available for replay for 60 days at http://public.viavid.com/index.php?id=143390 and on the investor relations section of the Company's website at www.ProPhaseLabs.com.
About ProPhase Labs
Lesen Sie auch
ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements brand. The Company’s subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), offers COVID-19 and other Respiratory Pathogen Panel (RPP) Molecular tests. The Company also continues to actively pursue strategic investments and acquisition opportunities for other companies, technologies and products. For more information visit us at www.ProPhaseLabs.com.